Diabetic Limb Salvage: Advanced Options in Wound Healing
Very briefly since I have no voice yesterday to give my talk, I'm going to go ahead and use this opportunity to give a brief overview of Diabetic Limb Salvage. Weve had some great discussion thus far at the conference particularly on Charcot foot at a fabulous Thursday morning session for those of you that were there discussing and really having an open forum discussion on some of the challenging cases that we face particularly looking at Charcot reconstruction and diabetic limb salvage. I want to go through with you some opportunities and some interest; we check the slight advance there.
On the identification of problem wounds and the concept here is to realize that these individuals fit into two categories. We have persons who were healing and persons who were not healing. Weve had some discussion earlier about a wonderful paper in diabetes care that you can see listed at the bottom here at 2003 published by Peter Sheehan that really outlines for some timelines and trajectories to understand that every wound has a trajectory. And that trajectory is either towards non-healing or as towards healing. And what we should be looking for if you boil all this down is that when youre taking your length times width measurements, it was not healing 10 to 15% per week and youre seeing that patient on a weekly basis. When you get to the 3rd or 4th week and youre still not seeing 10% to 15% healing, you need to step back and reassess this wound site and realize that you may now need to shift from the left hand side of the screen being basic wound care to the right hand side of the screen where this wound has failed basic therapy and you need to go into some level of advanced therapy technology. Now, there also is an opportunity at this point to step back and reassess the wound. You may need some rediagnosis for this wound. You may need some additional radiographic evaluation. You may need some additional biopsies or culture results that will help guide which we do it for this individual. But the reality is that you need to be able to reassess this and move on to the right direction.
Wound bed preparation. This is the term that weve batted around a little bit already at this conference and the concept here is that were trying to establish a wound that is ready to move on to the next step. When the wound is ready to move to the next step, you would consider it prepared given the treatment parameters that you have established for it. So one of the mistakes we make sometimes when we prescribe some of these advanced technologies or therapies for wounds is we dont necessarily have a goal or an endpoint while weve written that prescription or when we put them on a new dressing or when we put on a new kind of graft. We havent pre established in their mind. What it is that I'm looking for to declare this a success and know when do I move on to the next step? So thats something that we need to identify and be able to move forward with.
Bioengineered Alternative Tissues. This is the term that we coined just to kind of catch all the catchall term for what was becoming a great confusing terminology mix of skin substitutes and skin graft substitutes and bioengineer tissue. We didnt really know what to make of all this, but you can really fit all this into this category when you talk about bioengineered alternative tissues and tissue generation.
The science of bioengineered alternative tissue particularly looking at the living tissues during this discussion, I want to highlight some of the top process and what goes into the living tissue grafts apligraft and dermagraft, the cell therapy part of this is obviously what were actually trying to achieve. Were receiving growth factors cytokines and natural antibiotic production from these living cells that were delivering or somewhat transplanting onto the wound. And I encourage on, weve certainly probably heard this terminology before that when you put on apligraft or a dermagraft and you put on a living tissue substitute or a tissue product, you have to think of this as a sheet of growth factors and a sheet of cells rather than a piece of skin. If you think this as a piece of skin, you probably going to use it at the wrong time in the wrong patient. If the wound is ready for a piece of skin, you probably should use a piece of skin and get a piece of the skin graft and heal the wound. Were usually using these bioengineered tissues way before the wound is really ready for skin graft.
The role of fibroblast in wound healing and the concept here is to understand that although we may like to think that were past this biology that we took way back when in undergrad in podiatry school, but the reality is that a lot of this does tie back to cellular biology and much of what we get from using this living tissue products comes from the human fibroblast. If we can deliver healthy fibroblast onto a wound that doesnt itself have the ability to contain or produce or sustain healthy fibroblast, then were going to artificially stimulate healing in this wound site and you can see the products and the co-factors that are direct tributaries from a viable fibroblast. So again, the concept and a lot of questions coming about the platelet growth factors and such is the strong role for those in wounds. But if you truly think that it is a cellular deficiency or if you have some clinical evidence that tell you that you have dysfunction at the level of the wound on a biological level, then why would more of the same help the wound. We need to bring in something from the outside and thats what we can do with this living tissue grafts.
In particular, the bi-layer tissue therapy or trade name of apligraft this has four basic components, the surface are cornified layer which is exposed to air, the final manufacturing process actually contains keratinocytes as well as the epidermal layer. The dermal layer underneath is where the human fibroblast were found and thats all seated on top of it and extracellular matrix which is bovine type I collagen.
Now, early on this slide was used a lot by the manufacturers to show at the top kind of a cartoon picture but then at the bottom in a photomicrograph to show the product versus human skin and the similarities are amazing and they should be quite proud of the fact that they were able to reproduce what looks and feels somewhat like human skin in the laboratory using these tissue cell banks. But the reality is that this really is not the reason I use these products. If I need a skin, again, I would go to the thigh and I would take a skin graft and I would put it on the wound. The reality is that what were using this for as a biology of the fibroblast and the biology of the collagen and the keratinocyte that were delivering to the wound site, in my experience, you lose all if not most of this structure and this actual framework within 24 to 48 hours after applying the graft on the wound site. I dont take the dressing off and find that there is still sheet of tissue and find a big slurry of cells and a mass of coagulant, but the reality is thats still a viable successful graft patient. You just need to let that sit there and do its job for 3 to 4 weeks.
The characteristic of bi-layer cell therapy again, this is neonatal cell, its not fetal. People get very anxious about this from vorted tissue or is there an ethical boundary here thats been crossed. This is neonatal. These are healthy kids that are out running around playing basketball today who have had a circumcision and their tissue rather than being thrown to pathology is taken to the cell banks and used to generate this large cell banks and they have harvested a total of 10 to 15 graft in order to keep this cell banks viable. So, theres very minimal ethical concern here. We have cells that are producing cytokines, matrix proteins, antimicrobial peptides and complex epidermis which are generated from the wound margins.
Some of the FDA clinical trial data for this and efficacy, and in particular looking at apligraft, these are venous leg ulcerations greater than a year duration. This is where you really start to see some of the benefit using this product in your most difficult hard to heal patients at 4 weeks, 8 weeks, 12 weeks and 24 weeks seeing a significant difference of the control group and the active group healing almost 50%.
In the diabetic foot ulcer clinical trial for the FDA, this showed a significant lower rate of osteomyelitis and those who received the bi-layer cell therapy.
And this has open up a whole new clinical venue of these patients for wound healing. I share with you a clinical example here of a patient obviously have an aggressive foot infection traversing from the plantar spaces into the dorsal spaces involving the first ray but obviously also involving significant portion of the dorsal soft tissues.
If we were to evaluate this and debride it, this ended up for a complete disarticulation of
The first metatarsal and the first ray. We then progress to negative pressure therapy and hyperbaric oxygen to stimulate a deep tissue coverage for this patient and then progress on the bioengineer alternative tissues.
So once we got to a mostly healthy granular bed and had most of our deep tissues covered, we then progress on to the bi-layer of self therapy. You can see the migration from the wound margins.
We applied our second graft at the five week post grafting mark and a third graft
Was finally used to heal this patient.
Negative pressure wound therapy can be used in conjunction, its not necessary when youre talking about bioengineered tissues but certainly can be used in conjunction. Great study here published in Lancet at 2005 by Dave Armstrong and Larry Lavery that showed the role of negative pressure wound therapy really is in that wound bed preparation. Its in preparing the wound to move on to the next step increasing the rate of granulation tissue and the rate of healing.
Some early experience with us at Georgetown with negative pressure wound therapy when we initiated this for our patients in comparing to control, we found that we decrease the length of stay on average by 3 days for our inpatients and those who were receiving negative pressure wound therapy as part of their comprehensive surgical plan as opposed to those who were not, we decrease our rate of cross contamination. Doing dressing changes on the floor can be a very hazardous type of procedure versus every 3 to 4 days with the negative pressure therapy system, youre decreasing that chance of cross contamination. And we also have been utilizing this very significantly at our surgical closure site in BK and TMA amputations and have a significant decrease in our dehiscence and re-infection rates.
Couple of clinical examples here with a 39-year old gentleman plantar ulceration obviously of a mechanical nature. If we dont deal with the mechanics, it doesnt matter what biology we throw on top of this wound were going to continue to fail. So this particular gentleman we can see his x-rays.
No real significant concerns here but he
Had functional equinus is that all kinds of topical wound care with no real improvement to the wound and then finally
Upon progression, you can see what debridement and casting was able to get for so we got a healthy granular wound bed with adherent wound edges and weve got it to where its clean enough now that we feel comfortable proceeding to the operating room.
This is a gentleman that we did a debridement percutaneous tendo Achilles lengthening applied after graft and put them into a splint.
His post debridement culture shows no growth so we have a healthy wound bed without significant contamination and he healed rapidly in the next couple of months. Mostly due to the mechanical correction that we achieved from the tendo Achilles lengthening, but since we had such a chronic wound site, I felt that we need to give this someone of a biologic boost and thats what we did by using the bi-layered living cell therapy.
Another example here, we have dorsal and plantar wound status post incision and drainage, however this IND was incomplete because theres a residual osteo of the 4th and 5th ray. We debrided this as you can see in the right hand photo to the point of a partial 4th and 5th ray amputation.
Progressed on for kind of a comprehensive approach here for how were going to save this foot, counseling the patient that probably a TMA would be indicated here but if you want to try and save as much of your foot as possible, we certainly can attempt with some biologic tissue augmentation and what we did first was Integra with negative pressure wound therapy progress on to apligraft and then
Progressed on to a split thickness skin graft. So we kind of use all these products to prepare us for the next one. Integra to Apligraft to split thickness skin graft.
Real briefly on diabetic foot infection, important to distinguish between a closed diabetic foot infection or mostly a cellulitis versus an open diabetic foot infection or oftentimes a deep abscess or an osteomyelitis. Closed infections are usually responders that are rapidly responding to an antibiotic course, however, obviously having to distinguish those from a necrotizing fasciitis or some type of a true gas gangrene. Open wounds are generally more chronic. Theyve been exposed to multitude and number of organisms that are present and this can be significant challenges because of the need for a stage approach. We generally can't take a wound thats been open for two years, take them to the operating room, and cut up the metatarsal head and suture close the wound. Were going to end up with a massive dehiscence and probably an abscess that was created like closing that wound. So we stage these procedures in combination with the
Appropriate antibiotic therapy you see during a 3 to 5 day spacing between the debridement and the closure. Systematic approach to diabetic foot infection here obviously
A rather important part of what were talking about and its important when were looking at diabetic foot infection to distinguish and prioritize between infection and ischemia. If you dont have this thought process as your initial screening step when youre going through this patient in the emergency room in your clinic, in the office, in the hospital bed, you have to be able to prioritize this, this is a major medical legal risk factor in dealing with the diabetic foot. A number one reason, a podiatric physician or surgeon will get sued but for a diabetic foot case is failure to consult a vascular surgeon or failure to intervene early with revascularization in these patients that end up with proximal amputation. You dont want the evidence to come back and look for your chart to say that we think we could have prevented this below knee amputation that resulted from your care if the physician had gotten an earlier vascular consultation. It should be part of your initial work up for this patient a non-invasive vascular exam and if that shows any concerns, then theyre moving for an angiogram and a vascular surgery consultation. There are many situations where any gangrenous forefoot.
We will wait until the revascularization has been completed before we do any debridement. As long as there is no infection threat, were concern for abscess. We talked of Thursday about culturing and I thought I would throw this slide up for you just to back up what we had talked about of the concern of how important cultures can be or sometimes how misleading cultures can be and how they are taken.
This is a great study that was published in 2004 in diabetes medicine that looked at 60 infected foot wounds. Two cultures were taken from every wound. One was a superficial culture taken prior to debridement which we generally said was a bad idea and one was a deep culture taken after the debridement which is generally what we said was a good idea. The concept here in these individuals was I found that the swab and the deep tissue cultures were identical only in 62% of these cases which meant that a swab contain all organisms plus that contaminants 20% of the time and the swab failed to diagnose the deep actual organism, another almost 20% of the time. So if you rely on superficial swabs to guide your antibiotic therapy, youve got a 40% chance of being wrong with what youre actually treating this patient for, so deep tissue biopsy and culture swabs are what are scientifically indicative for this patient.
The Infectious Disease Society of America has established some pre-significant guidelines for the use of antibiotic therapy in the diabetic foot, I encourage you to review this if this makes a significant part of your practice. They have established the criteria for mild, moderate or severe infections looking at what medications orally and parenterally can respond to this therapy.
There is some distinction and some concern of a lot of piptasor or Piperacillin in combination which is better known as Zosyn by its trade name versus some concern for Ertapenem which has come out for a little more recently. Its a once a day drug that has certainly a significant indications for the diabetic foot
And have a great FDA trial showing their relevance and importance. Ill share with you a quick clinical example here of a patient that really drove home the message to me of just how severe and how rapid the changes can be in diabetes for foot infection. We oftentimes have this tendency to disbelieve our patients. And a patient comes in the ER, they say, oh they got a horrible malodorous foot with drainage and gangrene and just to looks like its as a disaster for of a train wreck thats probably going to lead to an amputation and he say, Ive only had this for 3 or 4 days. In the back of your mind youre thinking liar, liar, and liar. And in reality it can be true. Although many of those cases, the patients are in denial and then at the cases they dont have a good visions so they dont see the infection. They dont come to the hospital soon enough and because of neuropathy as we know, they dont have the pain that we would expect them to have from that infection. But Ill share with you one example, this patient came into our clinic longstanding diabetic patient with neuropathy. He said prior concerns and prior ulcerations and prior cellulitis all responded well to outpatient. He comes in with this infection that the slide doesnt really do a justice but he has got a cellulitic foot. Hes got fluctuance on the bottom of his foot. Hes got some fever and chills and we explain to him this is very different from your previous infections. This is a emergency. You need to come to the hospital this time. You need to be admitted today. Were going to operate tonight. Were going to try and save your foot. But you may end up with an amputation. This is a bad infection coming from this somewhat nondescript ulceration. Patient refuses, refuses, refuses. We spent 45 minutes going over the AMA guidelines and the fact that this gentleman is if he leaves the office, hes leaving against our advice and we just couldnt get through. We tried, we tried again, we couldnt get through. And I finally gave up and I said, you know what, you know what the risk is here sir, you know what weve advised you to do, you may against that, I can spend any more time with you, Ive got to move on to the next patient. And we wrote him what he requested, whats his prescription for his Cipro clinda. And weve explained to him please come to the ER as soon as you can so we can get you admitted. This gentleman showed up four days later in emergency room. And this is what his foot look like.
And to me this was rather dramatic. I know this going to get worse. I know he was going to end up to the point that he probably would up on amputation. But I didnt expect to see this amount of change over four days. So this kind of reaffirmed my belief in some of those patients who, say its only been there a few days only a few days. It can go from this to this in just a matter of days. And of course this patient progress on to below knee amputation.
Real briefly, I want to talk to you, I mentioned there was a great study done in regards to Ertapenem. The concept here is what was called the side step study. This is led by Ben Lipsky whos a real pioneer in the IDSA in the diabetic foot world. This is a large study 473 specimens that were obtained that base line looking at cultures, looking at patients.
The primary endpoint was to compare the clinical efficacy of ertapenem versus Pip-Tazo at the point of discontinuation of IV therapy and secondary this was to look at follow-up after they
Were on Pip-Tazo if indicated. This was a randomized double blind control trial with 586 patients enrolled in randomized. They received ertapenem one gram q. day versus Pip-Tazo 3.375 every six hours. They were classified according to the UT system and additional radiographic and a clinical test were utilized.
To sum up all that, in one slide for you is the story that we have, additional clinical options for us oftentimes ertapenem 3 can be a more convenient, a more cost effective, those schedule for your patient and they prove that they were at least clinically sufficient and equivalent to the Pip-tazo every six hours. So weve got additional options that are evolving for us in
treatment for the diabetic foot. Prevention of recurrence is a large, large challenge. We talked about this earlier with talking about patient compliance and denial and progressing with care against medical advice. These patients need appropriate patient education. We dont necessarily always have the time to do it, but we are the best suited provider to inspire them to do it. If we can get these patients to believe that they can make a difference in their disease, then theyll go on to seek the appropriate education that we can point them towards accommodating the deformity obviously weve talked about that and recognizing the actual true
And appropriate etiology of the ulceration. Thank you very much.
|Goals and Objectives|
After participating in this activity, the viewer should be better able to:
1. Identify the difference between good wound care and advanced wound care.
2. Choose the appropriate advanced wound modality at the appropriate time.
3. Assess the concept of wound bed preparation.
4. Appropriately treat diabetic wound infections.
Estimated time to complete this activity is 30 minutes.
Physicians, diabetes educators, and other health care professionals who treat patients with diabetes.
Complete the 4 steps to earn CE/CME credit:
It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.John Steinberg, DPM has no relevant financial relationship(s) to disclose.
This web site will respect the confidentiality of the information that is transmitted on it in accordance with the provisions of this Agreement. The Web Site uses a random identifier, which is a session number attributed to the Registered User as he enters the site. This session number is expunged of the Web Site system as Registered User leaves. Please be advised that the Registered User's visit to the Web Site leaves a retrievable trace that allows the Web Site to gather raw data on the Registered User. Such technical retrieving system is necessary in order to secure the Web Site system.
This web site uses statistic and measurement systems which compile and process information such as IP numbers and number of visited pages. This information is processed in order to establish members' profiles and trends that may lead to, for example, market studies.
By registering to Web Site services, the Registered User agrees that his/her personal information may be archived in the members database of the Web Site and be used to transmit newsletters published by the Web Site and communications such as press releases or commercial information by the Host.
Information We Collect
Information We Collect from Unregistered Visitors
Visitors to each of our Web sites can access the Web site's home page and browse some areas of the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you. On most of our Web sites, you must register with us to use the entire site.
Information We Collect When You Register
Customers registering for services on our Web sites are asked to provide us with identifying information, such as name, gender, contact information, and other personal information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion. You will also be given a choice about whether or not you want to receive newsletters and other information that we distribute from time to time. This PRESENT e-Learning Systems Web site will explain how personally identifiable information will be used and ask for your consent before collecting it.
Discussion Boards: When you use a discussion board on one of our Web sites, you may post a message and your user name, which is available for all registered users to see. When you are posting publicly, any user of our Web site can see your message. You should not post any information you want or are required by law to keep private to a discussion board or other public forum on our Web sites.
My CV (Curriculum Vitae): On our web site, we offer an online data based profiling tool in which you supply information that is part of your curriculum vitae or professional resume. This tool stores the information that you provide on our servers. The information is accessible by other members and the public, and is designed to advertise you to the online community and allow other's to find you based on the information that you provide. We will always make it clear to you when information you provide to us through a tool will be saved.
Member Lookup: On our website, other members will be able to look you up and send you messages. If you opt not to be listed (blocked), no other members will be able to look you up.
In addition, we gather information about you that is automatically collected by our Web server, such as your IP address and domain name. We will use this information to personalize its offerings and presentations to you, facilitate your movements throughout our Web sites, provide personalized services, and to communicate with you individually.
Continuing Medical Education
When you register for a Continuing Medical Education ("CME") or a Continuing Education ("CE") activity through our web site, we collect certain personally identifiable information from you such as your name, email address and mailing address. We require that you provide the state in which you are licensed and your license number. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:
(i) We are accredited by the Accreditation Council for Continuing Medical Education ("ACCME") to provide continuing medical education for physicians, through a sponsorship agreement with the Mount Sinai School of Medicine. As an ACCME accredited entity, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years;
(ii) Commercial supporters of CME/CE activities on our Web site will receive only a data about CME/CE activities that are relevant to their interests and/or the courses they support;
Uses We Make of Information
We collect data about visitors to our Web sites for product development and improvement activities. We also use it for market analysis. We may provide information from our Web sites in aggregate form, with identifying information removed, to third parties. For example, we may tell a health care partner what percentage of our registered users are of a particular medical specialty or have certain credentials. Any third party that receives our data must agree not to attempt to re-identify the people it belongs to. For example, we may provide information to a potential advertiser of a product that would appeal to a diabetes patient about what percentage of our users have diabetes. Depending on our agreement with the third parties, we may or may not charge for this information.
Marketing and Advertising
We may target our advertising or marketing depending on information we have about you. For example, a user that is a healthcare professional who treats diabetes may receive advertising for new diabetes therapies (although in neither case will the advertiser have access to any individually identifiable information about you). We may also personalize our Web site based on your interests. For example, you may see different articles in different places on our Web site based on information you have shared with us, or information we have gained by observing your previous behavior, or information we may have gained from your interactions with a third party that shares information with us. We use information for our own internal marketing, research, and related purposes. Third Parties In addition to aggregate information (discussed previously), we may share some kinds of personally identifiable information with third parties as described below.
Other Companies: We have strategic relationships with other companies who offer products and services on our Web sites. When you are interacting with those companies, different rules and privacy policies may apply. We do not control the collection or use of information you provide to these companies, but we do require that those companies clearly state their policies so you can decide whether to give them any information.
Promotional Offers: Sometimes we send offers to selected groups of customers on behalf of other businesses. When we do this, we do not give that business your name and address. We provide a variety of mechanisms for you to tell us you do not want to receive such promotional offers. For example, we may provide an opt-in box for consumers to receive an email from another business, and we make clear that by opting in you are submitting your data to a third party.
Protection of Information
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. We use security methods to determine the identity of its registered users, so that appropriate rights and restrictions can be enforced for that user. Reliable verification of user identity is called authentication. We use both passwords and usernames, as well as double opt-n verification, to authenticate users. Users are responsible for maintaining their own passwords.
Access to Information and Choices
Correction of Information We Have About You
If you believe that registration information collected by our Web site(s) is in error, you may edit your personal profile any time that you like. You can directly edit most of your user profile on the Web site on which you initially registered. Information that you can not edit may only be changed by contacting Web Customer Support (see CONTACTS). Requests for deletion of your record may result in your removal from the registry, but we may keep certain demographic information about you for product improvement purposes. You may contact Web Customer Support and ask for the changes that you would like to make.
This website and its content is copyright of PRESENT eLearning Systems, LLC - © 2007-2012 All rights reserved. Any redistribution or reproduction of part or all of the contents in any form is prohibited other than the following:
You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other website or other form of electronic retrieval system.